TrialAdvances in therapy2026

Pharmacokinetics, Pharmacodynamics, and Safety of Once-Weekly Insulin Efsitora Alfa in Chinese Patients with Type 2 Diabetes: A Phase 1 Open-Label, Randomized, Active-Controlled Trial.

Hui Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.